rifampisiini

Rifampisiini, commonly known as rifampin in English, is a semi-synthetic antibiotic derived from the bacterium Streptomyces mediterranei. It belongs to the rifamycin class and is primarily used to treat a variety of bacterial infections, including tuberculosis, leprosy, and certain types of meningitis. Rifampisiini works by inhibiting bacterial DNA-dependent RNA polymerase, thereby halting bacterial RNA synthesis and preventing further growth and replication.

The drug is often prescribed in combination with other antibiotics to combat multidrug-resistant strains of bacteria, such as Mycobacterium tuberculosis. It is also used prophylactically to prevent meningococcal and Haemophilus influenzae infections in individuals exposed to these pathogens. Rifampisiini is available in oral and intravenous formulations, with oral administration being the most common route.

Common side effects of rifampisiini include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. It may also cause hepatotoxicity, particularly when used in high doses or for prolonged periods. The drug is known to induce liver enzymes, which can affect the metabolism of other medications, potentially leading to drug interactions. Rifampisiini can also cause a reddish-orange discoloration of bodily fluids, such as urine, sweat, and tears, which is generally harmless but may be cosmetically concerning.

Due to its strong antibacterial activity and ability to penetrate the central nervous system, rifampisiini is considered a critical drug in the treatment of serious infections. However, its use is monitored closely due to the risk of resistance development, particularly in tuberculosis treatment regimens. Proper dosing, adherence to treatment plans, and regular monitoring are essential to maximize efficacy and minimize adverse effects.